创新药概念持续走强，医疗创新ETF(516820)上涨0.57%

Group 1 - The medical innovation ETF (516820) has seen a 0.57% increase, with significant gains in constituent stocks such as Haizhi Science (10.00%) and Kanghong Pharmaceutical (2.04%) [1] - Haizhi Science has received IND approvals for multiple innovative drugs, indicating a positive trend in the innovative drug sector [1] - CITIC Securities points out that the innovative drug industry is experiencing a favorable policy environment, with domestic companies gradually increasing their performance, signaling an upcoming harvest period [1] Group 2 - The total healthcare expenditure in China is expected to achieve stable and sustainable growth, with a focus on identifying sub-sectors that can outpace the average industry growth rate [2] - Key themes for long-term growth in the pharmaceutical industry include innovation, consumption upgrades, and high-end manufacturing [2] - The medical innovation ETF (516820) is positioned to capture opportunities in quality leading companies that may have been undervalued [2]